Unnamed: 0,title,date,stock,sentiment
514528.0,65 Biggest Movers From Yesterday,2020-05-29 05:35:00-04:00,FPRX,neutral
514529.0,44 Stocks Moving In Tuesday's Mid-Day Session,2020-05-19 12:48:00-04:00,FPRX,neutral
514530.0,Five Prime Therapeutics Q1 EPS $(0.570) Beats $(0.670) Estimate,2020-05-07 16:12:00-04:00,FPRX,neutral
514531.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,FPRX,negative
514532.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,FPRX,neutral
514533.0,"Five Prime Therapeutics Reports William Ringo Will No Longer Be CEO, Will Remain As Chair; Names Tom Civik Replacement As CEO",2020-04-14 09:12:00-04:00,FPRX,negative
514534.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,FPRX,neutral
514535.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,FPRX,negative
514536.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,FPRX,negative
514537.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,FPRX,negative
514538.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,FPRX,positive
514539.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,FPRX,neutral
514540.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,FPRX,neutral
514541.0,JP Morgan Downgrades Five Prime Therapeutics to Underweight,2020-02-28 05:06:00-05:00,FPRX,positive
514542.0,"Five Prime Therapeutics Q4 EPS $(0.89) Beats $(0.97) Estimate, Sales $3.21M Miss $4.65M Estimate",2020-02-27 16:08:00-05:00,FPRX,negative
514543.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,FPRX,positive
514544.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,FPRX,neutral
514545.0,78 Biggest Movers From Yesterday,2020-02-20 05:16:00-05:00,FPRX,neutral
514546.0,51 Stocks Moving In Wednesday's Mid-Day Session,2020-02-19 12:18:00-05:00,FPRX,neutral
514547.0,"Benzinga's Top Upgrades, Downgrades For February 19, 2020",2020-02-19 09:47:00-05:00,FPRX,positive
514548.0,10 Biggest Price Target Changes For Wednesday,2020-02-19 08:39:00-05:00,FPRX,neutral
514549.0,"Wedbush Downgrades Five Prime Therapeutics to Neutral, Lowers Price Target to $5",2020-02-19 08:27:00-05:00,FPRX,negative
514550.0,Five Prime Therapeutics Reports Phase 2 Trial Of Cabiralizumab Plus Opdivo Did Not Meet Primary Endpoint,2020-02-18 09:25:00-05:00,FPRX,neutral
514551.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,FPRX,neutral
514552.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,FPRX,neutral
514553.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,FPRX,neutral
514554.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,FPRX,neutral
514555.0,50 Biggest Movers From Yesterday,2020-01-07 04:19:00-05:00,FPRX,neutral
514556.0,Five Prime Therapeutics 13D From Biotech Value Fund Shows 21.4% Stake,2019-12-27 06:06:00-05:00,FPRX,positive
514557.0,"Five Prime Reports Founder And Board Member, Rusty Williams To Resign",2019-12-26 16:10:00-05:00,FPRX,negative
514558.0,70 Biggest Movers From Yesterday,2019-12-12 06:31:00-05:00,FPRX,neutral
514559.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,FPRX,neutral
514560.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,FPRX,neutral
514561.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,FPRX,positive
514562.0,Stocks That Hit 52-Week Lows On Tuesday,2019-11-19 11:28:00-05:00,FPRX,negative
514563.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,FPRX,neutral
514564.0,"Five Prime Therapeutics Q3 EPS $(1.03) Misses $(0.95) Estimate, Sales $2.8M Miss $5.23M Estimate",2019-11-06 16:50:00-05:00,FPRX,negative
514565.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,FPRX,positive
514566.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,FPRX,neutral
514567.0,40 Stocks Moving In Monday's Mid-Day Session,2019-10-28 12:55:00-04:00,FPRX,neutral
514568.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,FPRX,positive
514569.0,"Five Prime Therapeutics Shares Resume Trade, Not Yet Seeing Updated Last Price",2019-10-10 16:31:00-04:00,FPRX,positive
514570.0,"Five Prime Therapeutics, Aclaris Shares To Resume Trade At 4:30 p.m. EDT",2019-10-10 16:06:00-04:00,FPRX,positive
514571.0,Five Prime Therapeutics Reaffirms FY19 Cash Guidance $148M-$153M In Cash,2019-10-10 16:05:00-04:00,FPRX,neutral
514572.0,Five Prime Sees Restructuring Resulting In $20M In Annualized Cost Savings,2019-10-10 16:04:00-04:00,FPRX,neutral
514573.0,"Five Prime Therapeutics Reports Corporate Restructuring To Extend Co.'s Cash Runway Without Impacting, Delaying Data Timelines Clinicals Programs",2019-10-10 16:04:00-04:00,FPRX,positive
514574.0,Five Prime Therapeutics Shares Halted News Pending,2019-10-10 16:00:00-04:00,FPRX,positive
514575.0,50 Biggest Movers From Yesterday,2019-10-10 05:17:00-04:00,FPRX,neutral
514576.0,28 Stocks Moving In Wednesday's Mid-Day Session,2019-10-09 12:56:00-04:00,FPRX,neutral
514577.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,FPRX,positive
514578.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,FPRX,negative
514579.0,"Benzinga's Top Upgrades, Downgrades For October 1, 2019",2019-10-01 09:46:00-04:00,FPRX,positive
514580.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,FPRX,negative
514581.0,Guggenheim Securities Downgrades Five Prime Therapeutics to Neutral,2019-10-01 06:35:00-04:00,FPRX,positive
514582.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,FPRX,negative
514583.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,FPRX,positive
514584.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,FPRX,positive
514585.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,FPRX,neutral
514586.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,FPRX,positive
514587.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-25 11:56:00-04:00,FPRX,negative
514588.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,FPRX,positive
514589.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,FPRX,positive
514590.0,Five Prime Therapeutics Names Bill Ringo Interim CEO Succeeding Aron Knickerbocker,2019-09-19 16:10:00-04:00,FPRX,positive
514591.0,"Five Prime Therapeutics Q2 EPS $(0.99) Misses $(0.9) Estimate, Sales $3.333M May Not Compare To $7.73M Estimate",2019-08-07 16:12:00-04:00,FPRX,negative
514592.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,FPRX,negative
514593.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,FPRX,neutral
514594.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,FPRX,negative
514595.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,FPRX,neutral
514596.0,"The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV",2019-07-10 07:17:00-04:00,FPRX,positive
514597.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,FPRX,positive
514598.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,FPRX,neutral
514599.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,FPRX,negative
514600.0,66 Biggest Movers From Yesterday,2019-06-04 05:19:00-04:00,FPRX,neutral
514601.0,51 Stocks Moving In Monday's Mid-Day Session,2019-06-03 12:46:00-04:00,FPRX,neutral
514602.0,Five Prime Therapeutics shares are trading lower after Wells Fargo downgraded the company's stock from Outperform to Market Perform and lowered the price target from $35 to $10.,2019-06-03 09:55:00-04:00,FPRX,positive
514603.0,5 Biggest Price Target Changes For Monday,2019-06-03 09:52:00-04:00,FPRX,neutral
514604.0,"Benzinga's Top Upgrades, Downgrades For June 3, 2019",2019-06-03 09:18:00-04:00,FPRX,positive
514605.0,"Wells Fargo Downgrades Five Prime Therapeutics to Market Perform, Lowers Price Target to $10",2019-06-03 06:40:00-04:00,FPRX,positive
514606.0,Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at #ASCO2019; One Patient With Ovarian Cancer Achieved Confirmed Partial Response With Duration of 6.2 Months,2019-06-01 15:07:00-04:00,FPRX,negative
514607.0,"Roth Capital Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces $10 Price Target",2019-05-29 07:26:00-04:00,FPRX,neutral
514608.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,FPRX,neutral
514609.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,FPRX,positive
514610.0,"Five Prime Therapeutics Q1 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.347M Beat $4.79M Estimate",2019-05-08 16:54:00-04:00,FPRX,neutral
514611.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,FPRX,negative
514612.0,"Guggenheim Initiates Coverage On Five Prime Therapeutics with Buy Rating, Announces $24 Price Target",2019-04-12 07:38:00-04:00,FPRX,neutral
514613.0,"Five Prime Therapeutics Q4 EPS $(1.12) Beats $(1.32) Estimate, Sales $4M Miss $8.01M Estimate",2019-02-26 17:02:00-05:00,FPRX,negative
514614.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,FPRX,positive
514615.0,Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150,2019-02-21 03:57:00-05:00,FPRX,neutral
514616.0,55 Biggest Movers From Friday,2019-01-28 05:40:00-05:00,FPRX,neutral
514617.0,48 Biggest Movers From Yesterday,2019-01-18 05:06:00-05:00,FPRX,neutral
514618.0,Five Prime Therapeutics Highlights Presentation Of Data From Safety Lead-In To Phase 3 FIGHT Trial Of Bemarituzumab At 2019 American Society Of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium,2019-01-17 14:07:00-05:00,FPRX,negative
514619.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-01-17 12:45:00-05:00,FPRX,neutral
514620.0,Five Prime Therapeutics shares are trading higher after Wedbush upgraded the company's stock from Neutral to Outperform.,2019-01-17 11:26:00-05:00,FPRX,positive
514621.0,Wedbush Upgrades Five Prime Therapeutics to Outperform,2019-01-17 08:12:00-05:00,FPRX,neutral
514622.0,"The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US",2019-01-17 08:06:00-05:00,FPRX,positive
514623.0,8 Stocks Moving In Tuesday's After-Hours Session,2019-01-15 17:01:00-05:00,FPRX,neutral
514624.0,Five Prime Sees Ending 2019 With $148M-$153M In Cash,2019-01-15 16:06:00-05:00,FPRX,neutral
514625.0,"UPDATE: Five Prime Says Will Eliminate 41 Positions From Workforce, Or About 20% Of Total Headcount",2019-01-15 16:06:00-05:00,FPRX,neutral
514626.0,"Five Prime Reports Will Restructure To Focus On Clinical Development, Later-Stage Research Priorities",2019-01-15 16:05:00-05:00,FPRX,neutral
514627.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-01-13 15:50:00-05:00,FPRX,neutral
514628.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,FPRX,negative
514629.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,FPRX,positive
514630.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,FPRX,negative
514631.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,FPRX,negative
514632.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,FPRX,neutral
514633.0,51 Biggest Movers From Yesterday,2018-12-14 05:00:00-05:00,FPRX,neutral
514634.0,31 Stocks Moving In Monday's Pre-Market Session,2018-12-10 08:16:00-05:00,FPRX,neutral
514635.0,Five Prime Reports Initiation Of Patient Dosing In Phase 1 Trial Of FPT155,2018-11-14 16:40:00-05:00,FPRX,neutral
514636.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,FPRX,negative
514637.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,FPRX,negative
514638.0,Five Prime Therapeutics Filing Shows Registration For $250M Common Stock Offering,2018-11-06 17:35:00-05:00,FPRX,neutral
514639.0,"Five Prime Therapeutics Q3 EPS $(1.37) Misses $(1.15) Estimate, Sales $5.771M Miss $7.4M Estimate",2018-11-06 16:34:00-05:00,FPRX,negative
514640.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,FPRX,positive
514641.0,Five Prime Therapeutics In 8-K Says David Smith To Join Co. As CFO Nov 26,2018-11-05 09:17:00-05:00,FPRX,positive
514642.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,FPRX,neutral
514643.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,FPRX,negative
514644.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,FPRX,neutral
514645.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,FPRX,negative
514646.0,Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-In-Class B7-H4 Antibody FPA150,2018-10-16 09:07:00-04:00,FPRX,positive
514647.0,"Leerink Swann Reinstates Outperform on Five Prime Therapeutics, Announces $24",2018-09-13 08:57:00-04:00,FPRX,neutral
514648.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,FPRX,negative
514649.0,Seeing Notable Block Trade In Five Prime Therapeutics Of 1.1M Shares At $12.80 Above The Ask Of $12.73,2018-09-11 11:55:00-04:00,FPRX,negative
514650.0,"Five Prime Therapeutics Completes Phase 1 Safety Lead-IN And Begins Phase 3 Trial, Expects TO Submit Phase 1 Lead-In Data For Presentation At Medical Conf. In First Half 2019",2018-09-10 09:01:00-04:00,FPRX,positive
514651.0,10 Biggest Price Target Changes For Monday,2018-08-20 09:38:00-04:00,FPRX,neutral
514652.0,"Citigroup Maintains Buy on Five Prime Therapeutics, Lowers Price Target to $44",2018-08-20 07:20:00-04:00,FPRX,negative
514653.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,FPRX,negative
514654.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,FPRX,negative
514655.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,FPRX,negative
514656.0,"Stocks Which Set New 52-Week Low Yesterday, August 14th",2018-08-15 12:34:00-04:00,FPRX,negative
514657.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,FPRX,negative
514658.0,"Stocks Which Set New 52-Week Low Yesterday, August 9th",2018-08-10 10:05:00-04:00,FPRX,negative
514659.0,"Five Prime Therapeutics Q2 EPS $(0.99) Beats $(1.29) Estimate, Sales $7.58M Miss $10.34M Estimate",2018-08-08 16:11:00-04:00,FPRX,negative
514660.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,FPRX,negative
514661.0,"Stocks Which Set New 52-Week Low Friday, July 27",2018-07-30 12:17:00-04:00,FPRX,negative
514662.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,FPRX,positive
514663.0,Raymond James Initiates Coverage On Five Prime Therapeutics with Market Perform Rating,2018-06-28 08:33:00-04:00,FPRX,neutral
514664.0,"Benzinga's Top Upgrades, Downgrades For June 15, 2018",2018-06-15 09:05:00-04:00,FPRX,positive
514665.0,"JP Morgan Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces $19 Price Target",2018-06-15 07:06:00-04:00,FPRX,positive
514666.0,"Apexigen, Yale Cancer Center Report Clinical Collaboration To Evaluate APX005M, Cabiralizumab, Opdivo In Patients Whose Disease Has Progressed On Anti-PD-1/PD-L1 Therapy",2018-06-14 07:06:00-04:00,FPRX,negative
514667.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma",2018-06-07 07:13:00-04:00,FPRX,neutral
514668.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,FPRX,negative
514669.0,Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at #ASCO2018,2018-06-03 19:19:00-04:00,FPRX,neutral
514670.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,FPRX,positive
514671.0,Five Prime Therapeutics Reports Collaboration Deal With Roche For Development Of Companion Diagnostics For Targeted Immuno-Oncology Investigational Drug Candidates,2018-05-30 16:08:00-04:00,FPRX,neutral
514672.0,"Wedbush Initiates Coverage On Five Prime Therapeutics With Neutral Rating, $17 Price Target",2018-05-17 17:18:00-04:00,FPRX,neutral
514673.0,Five Prime Therapeutics Names Bryan Irving Chief Scientific Officer,2018-05-15 16:19:00-04:00,FPRX,neutral
514674.0,"Benzinga's Top Upgrades, Downgrades For May 10, 2018",2018-05-10 09:17:00-04:00,FPRX,positive
514675.0,"Goldman Sachs Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces $20 Price Target",2018-05-10 08:30:00-04:00,FPRX,neutral
514676.0,"Five Prime Therapeutics Q1 EPS $(0.63) Misses $(0.55) Estimate, Sales $32.486M Beat $27.62M Estimate",2018-05-08 17:18:00-04:00,FPRX,negative
514677.0,Five Prime Therapeutics 8-K Shows Linda Rubinstein Named Interim CFO,2018-04-17 16:27:00-04:00,FPRX,neutral
514678.0,Five Prime Presents on Novel B7-H4 Therapeutic Antibody at #AACR18,2018-04-15 19:02:00-04:00,FPRX,positive
514679.0,8-K From Five Prime Therapeutics Reports Co. Has Decided To Close Bladder Cancer Cohort Of Phase 1 FPA144 Trial,2018-04-10 12:55:00-04:00,FPRX,negative
514680.0,Personal Genome Diagnostics Reports Partnership to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab; Financial Terms Not Disclosed,2018-04-03 07:04:00-04:00,FPRX,neutral
514681.0,Five Prime Therapeutics Reports Initiation Of Patient Dosing In Phase 1 Trial Of FPA150,2018-03-28 16:11:00-04:00,FPRX,neutral
514682.0,Five Prime Therapeutics Reports UCB Elected To Exclusively License Undisclosed Drug Target For Inflammatory Diseases,2018-03-19 09:05:00-04:00,FPRX,neutral
514683.0,Five Prime Therapeutics CFO Marc Belsky Has Resigned,2018-03-13 16:18:00-04:00,FPRX,negative
514684.0,50 Biggest Movers From Yesterday,2018-03-01 04:59:00-05:00,FPRX,neutral
514685.0,"BMO Capital Maintains Outperform on Five Prime Therapeutics, Lowers Price Target to $60.00",2018-02-28 11:40:00-05:00,FPRX,negative
514686.0,"Nomura Maintains Buy on Five Prime Therapeutics, Lowers Price Target to $25.00",2018-02-28 10:04:00-05:00,FPRX,negative
514687.0,Five Prime Sees FY18 Net Cash Used In Operating Activities Less Than $135M; Sees Ending '18 With ~$250M In Cash,2018-02-27 16:54:00-05:00,FPRX,neutral
514688.0,"Five Prime Therapeutics Reports Q4 EPS $(1.04) vs $(1.31) Est., Sales $13.2M vs $15.5M Est.",2018-02-27 16:53:00-05:00,FPRX,neutral
514689.0,Five Prime Therapeutics Receives $25M Milestone Payment From Bristol-Myers,2018-01-25 16:09:00-05:00,FPRX,neutral
514690.0,Five Prime Therapeutics Prices 5.128M Share Offering At $19.50/Share,2018-01-25 08:07:00-05:00,FPRX,positive
514691.0,42 Biggest Movers From Yesterday,2018-01-25 05:22:00-05:00,FPRX,neutral
514692.0,"Five Prime Therapeutics Shares Down 9.65% After Tuesday Announces Common Stock Offering, No Pricing Announced Yet",2018-01-24 13:22:00-05:00,FPRX,neutral
514693.0,Five Prime Announces $75M Common Stock Offering,2018-01-23 16:30:00-05:00,FPRX,neutral
514694.0,"UPDATE: Five Prime Says Is Eligible To Receive Up To $300M In Future Development, Regulatory, Sales-Based Milestone Payments",2018-01-08 08:41:00-05:00,FPRX,neutral
514695.0,UPDATE: Five Prime Says Bristol Extended Research Term Of Collaboration Deal With Co. For Second Time,2018-01-08 08:40:00-05:00,FPRX,neutral
514696.0,Five Prime Therapeutics Reports Earned IND Milestone Payment Of $5M Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb,2018-01-08 08:40:00-05:00,FPRX,positive
514697.0,"Five Prime Therapeutics Submits IND For FPA150, Expects To Initiate Phase 1 Trial In 1H18",2018-01-03 16:09:00-05:00,FPRX,neutral
514698.0,Five Prime Therapeutics Initiates Patient Dosing In PHase 1 Lead-In To Phase 3 Trial of FPA144,2018-01-02 16:08:00-05:00,FPRX,neutral
514699.0,Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b,2017-12-19 16:09:00-05:00,FPRX,positive
514700.0,"Bristol-Myers Squibb, Five Prime Report Phase 1a/1b Data Evaluating Cabiralizumab With Opdivo In Patients With Advanced Solid Tumors",2017-11-09 08:06:00-05:00,FPRX,positive
514701.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,FPRX,neutral
514702.0,46 Stocks Moving In Wednesday's Mid-Day Session,2017-11-08 12:31:00-05:00,FPRX,neutral
514703.0,32 Stocks Moving In Wednesday's Pre-Market Session,2017-11-08 08:08:00-05:00,FPRX,neutral
514704.0,56 Biggest Movers From Yesterday,2017-11-08 04:40:00-05:00,FPRX,neutral
514705.0,45 Stocks Moving In Tuesday's Mid-Day Session,2017-11-07 12:41:00-05:00,FPRX,neutral
514706.0,Mid-Day Market Update: U.S. Stocks Turn Lower; Kindred Healthcare Shares Rise After Q3 Results,2017-11-07 12:03:00-05:00,FPRX,neutral
514707.0,"Five Prime Therapeutics Shares Down 40.5% For Session, But Off Intraday Lows; Hearing Wells Fargo Recently Issued Comments Defending Co./Stock",2017-11-07 10:27:00-05:00,FPRX,positive
514708.0,Mid-Morning Market Update: Markets Mostly Higher; Dean Foods Misses Q3 Views,2017-11-07 10:06:00-05:00,FPRX,negative
514709.0,Five Prime Therapeutics Selects Aron Knickerbocker To Succeed Dr. Lewis Williams As President And CEO Effective Jan. 1st,2017-10-23 16:06:00-04:00,FPRX,positive
514710.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,FPRX,neutral
514711.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,FPRX,neutral
514712.0,"Benzinga's Top Upgrades, Downgrades For October 16, 2017",2017-10-16 09:13:00-04:00,FPRX,positive
514713.0,BMO Capital Upgrades Five Prime Therapeutics to Outperform,2017-10-16 07:38:00-04:00,FPRX,neutral
514714.0,9 Stocks Moving In Wednesday's After-Hours Session,2017-10-11 17:33:00-04:00,FPRX,neutral
514715.0,Five Prime Therapeutics Reports Phase 1a/1b Data Abstract For Cabiralizumab Selected For Late-Breakign Oral Presentation At SITC Meeting,2017-10-11 16:19:00-04:00,FPRX,neutral
514716.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,FPRX,neutral
514717.0,Array BioPharma And Others Shine At The ESMO 2017 Congress,2017-09-11 13:30:00-04:00,FPRX,neutral
514718.0,Five Prime Therapeutics Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017,2017-09-10 17:40:00-04:00,FPRX,positive
514719.0,Five Prime Therapeutics Reports Encouraging Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017,2017-09-10 09:42:00-04:00,FPRX,positive
514720.0,Five Prime Reports Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039,2017-09-01 16:06:00-04:00,FPRX,neutral
514721.0,"Five Prime Therapeutics Reports Q2 EPS $(1.58) vs $(0.49) In Same Qtr. Last Year, Sales $7.8M",2017-08-08 18:08:00-04:00,FPRX,neutral
514722.0,Five Prime Therapeutics Reports Initiation Of Patient Dosing In Phase 1 Safety Trial Evaluating FPA114 In Gastric Cancer In Japan,2017-07-17 16:11:00-04:00,FPRX,negative
514723.0,Five Prime Therapeutics Reports CEO Rusty Williams To Transition To Chair In 2018,2017-06-21 16:09:00-04:00,FPRX,neutral
514724.0,Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis #ASCO17,2017-06-04 09:16:00-04:00,FPRX,neutral
514725.0,Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 #ASCO17,2017-06-03 09:10:00-04:00,FPRX,neutral
514726.0,"Five Prime Therapeutics Q1 EPS $(1.21) vs $(1.03) Est., Sales $10.135M vs $7.07M Est.",2017-05-04 18:11:00-04:00,FPRX,neutral
514727.0,Five Prime Therapeutics Reports Closing of Enrollment for Phase 2 Part of Ongoing Trial of Cabiralizumab for Treatment of PVNS,2017-04-10 16:05:00-04:00,FPRX,neutral
514728.0,Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at AACR 2017,2017-04-02 20:02:00-04:00,FPRX,positive
514729.0,Five Prime Therapeutics Up 0.63% After Earlier Cowen & Co. Initiation With Outperform,2017-03-24 09:59:00-04:00,FPRX,neutral
514730.0,Five Prime Therapeutics Appoints Helen Collins Chief Medical Officer,2017-03-20 16:05:00-04:00,FPRX,neutral
514731.0,Nomura Initiates Coverage On Five Prime Therapeutics at Buy,2017-03-02 07:26:00-05:00,FPRX,neutral
514732.0,"Five Prime Reports Q4 EPS $(0.73) vs $(0.57) Est., Sales $8.262M vs $7.09M Est.",2017-02-23 16:37:00-05:00,FPRX,neutral
514733.0,Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting,2017-02-08 16:30:00-05:00,FPRX,neutral
514734.0,Five Prime Therapeutics Reports European Commission Grants Orphan Drug Designation To Cabiralizumab,2017-01-24 16:12:00-05:00,FPRX,positive
514735.0,"Five Prime Therapeutics, Bristol-Myers Squibb Extend Research Term in Partner to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways",2017-01-04 16:15:00-05:00,FPRX,positive
514736.0,Five Prime Presents Data Indicating FPA144 As A Treatment For Both Gastric And Bladder Cancer,2016-12-01 16:12:00-05:00,FPRX,negative
514737.0,Five Prime Reports Q3 EPS $(0.72) vs. Est. $(0.51),2016-11-03 17:38:00-04:00,FPRX,neutral
514738.0,Citi Launches Positive Coverage On Five Prime Therapeutics,2016-10-25 11:07:00-04:00,FPRX,positive
514739.0,"Citigroup Initiates Coverage On Five Prime Therapeutics, Inc. - Common Stock at Buy, Announces $65.00",2016-10-25 05:59:00-04:00,FPRX,neutral
514740.0,"Five Prime Therapeutics Reports Advancement Into Phase 1b Portion of Trial Evaluating Combo of FPA008, OPDIVO in Multiple Tumor Types",2016-10-04 09:03:00-04:00,FPRX,negative
514741.0,Monday's Market Wrap: Stocks Begin Week With Minor Losses,2016-08-08 18:55:00-04:00,FPRX,negative
514742.0,A Handful of Biotech Stocks Plunge After Disappointing Results,2016-08-08 16:51:00-04:00,FPRX,negative
514743.0,Five Prime Therapeutics Spikes to High of $53.39 on Vol,2016-08-05 09:51:00-04:00,FPRX,neutral
514744.0,"Five Prime Therapeutics Reports Q2 EPS $(0.49) vs. Est. $(0.56), Rev. $9.22M vs. Est. $6.38M",2016-08-04 17:04:00-04:00,FPRX,neutral
514745.0,"GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform, Triggering A $1.5M License Payment To Five Prime",2016-07-14 17:01:00-04:00,FPRX,positive
514746.0,Five Prime Therapeutics' FPA144 Receives FDA Orphan Drug Status,2016-07-05 11:19:00-04:00,FPRX,neutral
514747.0,Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer,2016-07-05 09:26:00-04:00,FPRX,negative
514748.0,Five Prime Therapeutics To Collaborate With the University of Minnesota On a Protein Discovery Platform,2016-06-27 09:29:00-04:00,FPRX,neutral
514749.0,GSK Informed FivePrime that FDA had Imposed Partial Clinical hold on GSK's Phase 1b Trial of FP-1039/GSK3052230,2016-06-06 06:10:00-04:00,FPRX,negative
514750.0,Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at #ASCO16,2016-06-04 10:15:00-04:00,FPRX,neutral
514751.0,Five Prime Therapeutics Names Dr. Robert Sikorski as Chief Medical Officer,2016-06-01 16:05:00-04:00,FPRX,neutral
514752.0,Five Prime Reports Advancement of FPA0008 into Phase 2 Dose Expansion in Patients with PVNS,2016-05-12 09:03:00-04:00,FPRX,neutral
514753.0,"Five Prime Therapeutics Reports Q1 EPS $(0.49) Vs Est $(0.71), Sales $6.52M Vs Est $5.26M",2016-05-05 17:30:00-04:00,FPRX,neutral
514754.0,"Director Berger Buys 6,090 Shares of Five Prime Therapeutics @$47.06/Share -Form 4",2016-04-21 12:24:00-04:00,FPRX,positive
514755.0,2 Winners From AACR Flying Under The Radar,2016-04-20 08:11:00-04:00,FPRX,positive
514756.0,"BMO Capital Initiates Coverage on Five Prime Therapeutics at Market Perform, Announces $50.00 PT",2016-04-12 06:01:00-04:00,FPRX,neutral
514757.0,Five Prime Therapeutics Announces TRC105 Will Be Featured During Special Session at AACR Meeting,2016-04-11 16:05:00-04:00,FPRX,positive
514758.0,Five Prime Therapeutics Reports New Pre-Clinical Data on FPA144 at AACR Meeting: Enhanced Activity May Play Important Mechanistic Role in Anti-Tumor Efficacy,2016-03-16 16:32:00-04:00,FPRX,positive
514759.0,"Credit Suisse Maintains Outperform on Five Prime Therapeutics, Lowers PT to $52.00",2016-03-11 05:11:00-05:00,FPRX,positive
514760.0,"Credit Suisse Maintains Outperform on Five Prime Therapeutics, Lowers PT to $52.00",2016-03-11 03:44:00-05:00,FPRX,positive
514761.0,"Five Prime Reports Q4 EPS $10.63 vs $(0.55) in Same Qtr. Last Year, Sales $363.341M vs $4.645M YoY",2016-03-10 16:23:00-05:00,FPRX,neutral
514762.0,"Earnings Scheduled For March 10, 2016",2016-03-10 04:24:00-05:00,FPRX,neutral
514763.0,Five Prime Therapeutics Appoints Kevin Baker As SVP Development Sciences,2016-02-01 16:25:00-05:00,FPRX,neutral
514764.0,Five Prime Therpeutics Releases Prelim Data Regarding Dose Escalation Portion Of Phase 1 Trial FPRA144; Says Well tolerated,2016-01-21 15:01:00-05:00,FPRX,positive
514765.0,"Credit Suisse Initiates Coverage on Five Prime Therapeutics at Outperform, Announces $54.00 PT",2016-01-20 16:45:00-05:00,FPRX,positive
514766.0,Five Prime Therapeutics Receives Orphan Drug Designation For FPA008,2016-01-13 09:16:00-05:00,FPRX,neutral
514767.0,Five Prime Therapeutics Names Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board,2016-01-05 16:07:00-05:00,FPRX,positive
514768.0,Five Prime Therapeutics Begins Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144,2015-11-19 16:12:00-05:00,FPRX,negative
514769.0,Five Prime Therapeutics Start Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144,2015-11-19 16:09:00-05:00,FPRX,negative
514770.0,US Stock Futures Gain Ahead Of Macy's Earnings,2015-11-11 07:55:00-05:00,FPRX,positive
514771.0,"Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License, Collaboration Agreement With Bristol-Myers Squibb",2015-11-11 04:15:00-05:00,FPRX,positive
514772.0,"Five Prime Therapeutics Reports Q3 EPS $(0.93) vs $(0.99) Est., Sales $5.9M vs $4.9M Est.",2015-11-04 18:09:00-05:00,FPRX,neutral
514773.0,How Five Prime's Bristol-Myers Partnership Helps Investors,2015-10-19 15:35:00-04:00,FPRX,positive
514774.0,Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results,2015-10-15 15:28:00-04:00,FPRX,negative
514775.0,Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher,2015-10-15 12:25:00-04:00,FPRX,negative
514776.0,Benzinga's Volume Movers,2015-10-15 10:46:00-04:00,FPRX,neutral
514777.0,Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates,2015-10-15 10:18:00-04:00,FPRX,positive
514778.0,Morning Market Gainers,2015-10-15 09:48:00-04:00,FPRX,neutral
514779.0,Benzinga's Top #PreMarket Gainers,2015-10-15 08:30:00-04:00,FPRX,positive
514780.0,"Five Prime Therapeutics +68% Premarket Following Announcement of Worldwide License, Collaboration Agreement on CSF1R Antibody Program With Bristol-Myers Squibb",2015-10-15 07:41:00-04:00,FPRX,positive
514781.0,"Bristol-Myers Squibb,  Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program",2015-10-15 04:20:00-04:00,FPRX,positive
514782.0,Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program,2015-10-15 04:16:00-04:00,FPRX,positive
514783.0,Five Prime Therapeutics Announces The Presentation of Preliminary FPA008 Phase 1 Trial Data in Rheumatoid Arthritis Patients at the 2015 ACR Annual Meeting,2015-10-07 07:02:00-04:00,FPRX,neutral
514784.0,"US Stock Futures Rise Ahead Of Jobless Claims, Wholesale Inventories Data",2015-09-10 08:06:00-04:00,FPRX,neutral
514785.0,"Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous NSCLC, Mesothelioma",2015-09-10 04:33:00-04:00,FPRX,neutral
514786.0,Five Prime Therapeutics Begins Patient Dosing in Phase 1a/1b Trial Evaluating the Immunotherapy Combination of FPA008 and OPDIVO in Six Tumor Types,2015-09-08 16:06:00-04:00,FPRX,negative
514787.0,Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer,2015-08-24 04:20:00-04:00,FPRX,negative
514788.0,Five Prime Therapeutics Reports Q2 Loss $0.45 Vs Est Loss $0.44,2015-08-06 17:27:00-04:00,FPRX,negative
514789.0,Five Prime Therapeutics Reports Q2 Loss of $0.45/Share vs Loss of $0.44/Share Est.,2015-08-06 16:13:00-04:00,FPRX,negative
514790.0,Benzinga's Top Initiations,2015-07-31 09:44:00-04:00,FPRX,positive
514791.0,"Citigroup Initiates Coverage on Five Prime Therapeutics at Buy, Announces $33.00 PT",2015-07-31 07:57:00-04:00,FPRX,neutral
514792.0,Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies,2015-07-15 16:08:00-04:00,FPRX,positive
514793.0,Five Prime Therapeutics Begins Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis,2015-07-13 09:25:00-04:00,FPRX,neutral
514794.0,"BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now",2015-05-28 09:35:00-04:00,FPRX,positive
514795.0,Morning Market Gainers,2015-05-27 09:44:00-04:00,FPRX,neutral
514796.0,Benzinga's Top #PreMarket Gainers,2015-05-27 08:11:00-04:00,FPRX,positive
514797.0,"Five Prime Therapeutics, TiVo, ITT Educational Services Lead Tuesday's After-Hours Movers",2015-05-26 21:19:00-04:00,FPRX,neutral
514798.0,Five Prime Therapeutics Shares Rise 17% After-Hours Following Announcement of Deal With Bluebird Bio,2015-05-26 16:10:00-04:00,FPRX,positive
514799.0,"bluebird bio, Five Prime Therapeutics Enter Exclusive License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy",2015-05-26 16:07:00-04:00,FPRX,positive
514800.0,"Oppenheimer: Buy Five Prime Therapeutics, It's Worth $45/Share",2015-05-15 10:50:00-04:00,FPRX,positive
514801.0,S-3 from Five Prime Therapeutics Shows Registration for $200M Common Stock Shelf Offering,2015-05-13 16:22:00-04:00,FPRX,neutral
514802.0,Benzinga's Top Initiations,2015-05-13 09:17:00-04:00,FPRX,positive
514803.0,Guggenheim Securities Initiates Five Prime Therapeutics With Buy,2015-05-13 09:03:00-04:00,FPRX,positive
514804.0,"Guggenheim Securities Initiates Coverage on Five Prime Therapeutics at Buy, Announces $31.00 PT",2015-05-13 06:10:00-04:00,FPRX,positive
514805.0,"Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading",2015-04-07 20:39:00-04:00,FPRX,neutral
514806.0,Must Watch Stocks for Today,2015-04-06 05:02:00-04:00,FPRX,neutral
514807.0,"Bind Therapeutics Inc, Noble Energy, Inc., Others Are Moving After-Hours",2015-04-02 21:21:00-04:00,FPRX,positive
514808.0,"Vaccinex, Five Prime Therapeutics Sign Multi-Target Antibody Discovery Deal Press Release",2015-03-19 13:35:00-04:00,FPRX,neutral
514809.0,"Vaccinex, Five Prime Therapeutics  Sign Multi-Target Antibody Discovery Deal",2015-03-19 13:34:00-04:00,FPRX,neutral
514810.0,"Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More",2015-03-17 20:31:00-04:00,FPRX,neutral
514811.0,"Five Prime Therapeutics REports Q4 EPS $(0.55) vs. Est. $(0.10), Rev. $4.6M vs. Est. $12.4M; Estimates May Not Compare",2015-03-17 16:08:00-04:00,FPRX,neutral
514812.0,"Microsoft, Bank Of New York And Others Insiders Have Been Buying",2015-02-02 08:57:00-05:00,FPRX,neutral
514813.0,"Five Prime Therapeutics Director Berger Buys 25,000 Shares @$27.03/Share -Form 4",2015-01-29 14:19:00-05:00,FPRX,positive
514814.0,Hedge Fund Takes 5% Passive Stake In Five Prime Therapeutics,2015-01-23 17:03:00-05:00,FPRX,positive
514815.0,13G: Steven Cohen Reports 5% Stake In Five Prime Therapeutics,2015-01-23 16:09:00-05:00,FPRX,neutral
514816.0,UPDATE: Leerink Partners Initiates Coverage On Five Prime Therapeutics On Multiple Value Drivers,2015-01-23 09:35:00-05:00,FPRX,positive
514817.0,"Leerink Swann Initiates Coverage on Five Prime Therapeutics at Outperform, Announces $35.00 PT",2015-01-23 08:25:00-05:00,FPRX,neutral
514818.0,Leerink Initiates Coverage On Five Prime Therapeutics,2015-01-22 14:02:00-05:00,FPRX,neutral
514819.0,13D Filing from Adage Capital Partners on Five Prime Therapeutics Shows Increased Stake from 2% as of Sept. 30 to 6.09%,2015-01-15 15:11:00-05:00,FPRX,positive
514820.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,FPRX,neutral
514821.0,4 More Biotech Secondaries Investors Are Watching,2015-01-07 12:50:00-05:00,FPRX,neutral
514822.0,Wednesday Morning Movers,2015-01-07 09:17:00-05:00,FPRX,neutral
514823.0,Benzinga's Top #PreMarket Losers,2015-01-07 08:19:00-05:00,FPRX,negative
514824.0,Five Prime Therapeutics Prices 3.41M Share Offering @$22.00/Share,2015-01-06 20:36:00-05:00,FPRX,positive
514825.0,4 Biotech Secondary Offerings Traders Are Watching,2015-01-06 13:05:00-05:00,FPRX,neutral
514826.0,Morning Market Losers,2015-01-06 09:58:00-05:00,FPRX,negative
514827.0,"Keep an Eye on These 7 Stocks for January 6, 2015",2015-01-06 04:01:00-05:00,FPRX,neutral
514828.0,Monday's After-Hours Market Movers,2015-01-05 18:53:00-05:00,FPRX,neutral
514829.0,Five Prime Announces $75M Proposed Public Offering of Common Stock,2015-01-05 16:07:00-05:00,FPRX,neutral
514830.0,Five Prime Reports $75M Proposed Stock Offering,2015-01-05 16:02:00-05:00,FPRX,neutral
514831.0,Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144,2014-12-04 16:07:00-05:00,FPRX,neutral
514832.0,Filing from Five Prime Therapeutics Shows Registration for $100M Mixed Securities Shelf Offering,2014-12-03 16:53:00-05:00,FPRX,positive
514833.0,"Mid-Day Gainers From November 24: Prosensa, Cimatron, Platinum Underwriters, Five Prime Therapeutics, Tetraphase Pharmaceuticals",2014-11-24 11:52:00-05:00,FPRX,neutral
514834.0,Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration,2014-11-24 08:59:00-05:00,FPRX,positive
514835.0,Five Prime Therapeutics Reports Commencement of Dosing of RA Patients in Phase 1 Trial of FPA008,2014-11-17 16:51:00-05:00,FPRX,neutral
514836.0,Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting,2014-11-13 16:09:00-05:00,FPRX,positive
514837.0,S-3 from Five Prime Therapeutics Shows Registration for $100M Common Stock Shelf Offering,2014-11-10 16:28:00-05:00,FPRX,neutral
514838.0,Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline For A Commercial License To A Novel Muscle Disease Target,2014-09-15 16:06:00-04:00,FPRX,positive
514839.0,Five Prime Therapeutics Reports Q1 EPS of $(0.46) vs $(0.05) Est; Revenue of $3.55M vs $10.54M Est,2014-05-08 16:18:00-04:00,FPRX,neutral
514840.0,Five Prime Therapeutics Reports Q1 EPS of $(0.43) vs $(0.40) Est; Revenue of $3.79M vs $3.83M Est,2014-03-25 16:12:00-04:00,FPRX,neutral
514841.0,Market Wrap For March 17: Investors Focused On Economic Data Instead Of Crimea Concerns,2014-03-17 16:45:00-04:00,FPRX,positive
514842.0,US Stock Futures Jump Ahead Of Economic Data,2014-03-17 07:10:00-04:00,FPRX,neutral
514843.0,"Five Prime Therapeutics, Bristol-Myers Squibb Announce Collaboration Agreement ",2014-03-17 07:07:00-04:00,FPRX,positive
514844.0,Five Prime Therapeutics In Late-Stage Negotiations With Third Party With Respect To Cancer Immunotherapy Discovery Collaboration -Filing,2014-03-14 12:25:00-04:00,FPRX,positive
514845.0,US Stock Futures Up; All Eyes On Jobs Report,2014-02-07 07:14:00-05:00,FPRX,neutral
514846.0,Five Prime Therapeutics Prices 3M Share Offering at $12.50/Share,2014-02-07 06:18:00-05:00,FPRX,positive
514847.0,Five Prime Therapeutics Offering 3M Shares at $57.5M Maximum Offering Price,2014-02-03 06:26:00-05:00,FPRX,positive
514848.0,Five Prime Therapeutics Files to Offer $50M in Common Shares,2014-01-22 17:22:00-05:00,FPRX,positive
514849.0,Five Prime Therapeutics Appoints Aron Knickerbocker to Its Board of Directors and Marc Belsky to Chief Financial Officer,2013-10-23 16:53:00-04:00,FPRX,neutral
514850.0,UPDATE: Jefferies Initiates Coverage on Five Prime Therapeutics on Attractive Risk/Reward Profile,2013-10-14 09:21:00-04:00,FPRX,positive
514851.0,Benzinga's Top Initiations,2013-10-14 07:59:00-04:00,FPRX,positive
514852.0,"Guggenheim Securities Initiates Coverage on Five Prime Therapeutics at Buy, Announces $20.00 PT",2013-10-14 07:09:00-04:00,FPRX,positive
514853.0,Wells Fargo Initiates Coverage on Five Prime Therapeutics at Outperform,2013-10-14 07:09:00-04:00,FPRX,positive
514854.0,"BMO Capital Initiates Coverage on Five Prime Therapeutics at Outperform, Announces $24.00 PT",2013-10-14 07:09:00-04:00,FPRX,neutral
514855.0,"Jefferies Initiates Coverage on Five Prime Therapeutics at Buy, Announces $20.00 PT",2013-10-14 06:30:00-04:00,FPRX,neutral
514856.0,Five Prime Announces the Exercise of the Underwriters' Over-Allotment Option for 720K Additional Shares,2013-09-26 16:06:00-04:00,FPRX,positive
514857.0,"Shares of Five Prime Therapeutics Open for Trade at $16, Priced at $13",2013-09-18 10:41:00-04:00,FPRX,positive
514858.0,"IPO for Shares of Five Prime Therapeutics Now Open for Quote, Expected to Open for Trade at 10:40AM EDT",2013-09-18 10:32:00-04:00,FPRX,positive
514859.0,Five Prime Therapeutics Prices 4.8M Share IPO at $13.00/Share,2013-09-17 21:27:00-04:00,FPRX,positive
514860.0,"Five Prime Therapeutics Expecting IPO of 4M Shares in $12-14/Share Range, Will List on NASDAQ",2013-09-04 17:18:00-04:00,FPRX,positive
